The maintenance phase challenge What happens when you stop: Appetite returns (gradually over weeks) Need to rely on habits built during weight loss Risk of regaining weight if not careful Success factors: How long you maintained at goal weight while on peptides Habits built during weight loss phase Continued protein intake and training Realistic expectations (some people maintain perfectly, others regain some) Tapering off GLP-1s Don't quit cold turkey: Gradually reduce dose over 4-8 weeks Example: 2.4mg 1.7mg 1mg 0.5mg 0.25mg stop This allows appetite to return gradually Gives you time to adjust habits While tapering: Monitor weight weekly If starting to regain, slow taper Maintain protein intake religiously Keep training consistent Long-term maintenance options Option 1: Cruise dose Stay on low dose GLP-1 indefinitely (0.25-0.5mg weekly) Maintains some appetite suppression Prevents regain Safer long-term than high doses Option 2: Cycle on/off 3-4 months on, 1-2 months off Return to peptides if weight creeps up 5+ pounds Allows body breaks from medication Option 3: Switch to sustainable peptides Transition from GLP-1s to CJC-1295/Ipamorelin Maintains metabolic benefits Supports muscle and recovery No appetite suppression (must rely on habits) Learn how to structure long-term protocols in our peptide cycle planning guide
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
Patients with OSA caused by factors other than obesity may not experience the same benefits
If you are new to peptides entirely, read the Getting Started with Peptides guide before selecting a compound
(2025) NICE [accessed 15 January 2026]
This advanced, dual-action GIP and GLP-1 receptor agonist is specifically designed for elevated metabolic control, offering a more comprehensive approach than traditional single-pathway therapies
A recent survey of 251 current and former users gives us a closer look at how these changes are shaping real experiences in 2025
